Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis
Annals of Rheumatic Diseases, 06/21/2012  Evidence Based Medicine  Clinical Article

Isaacs JD et al. – Although the difference was modest, the overall–effect model indicates that seropositive patients respond better to rituximab than seronegative patients.

• This was a meta–analysis of four placebo–controlled, phase II or III clinical trials.
• The efficacy end point in all analyses was change from baseline in Disease Activity Score in 28 joints–erythrocyte sedimentation rate (DAS28–ESR) at 24 weeks.
• Assay of serotype and missing data imputation methods were consistent across all studies.

• The population analysed comprised 2177 patients (rituximab, n=1416; placebo, n=761).
• Demographics and baseline disease characteristics were well balanced.
• When a fixed–effects meta–analysis approach was used, the overall–effect model indicated evidence of additional treatment benefit with rituximab in seropositive patients: reduction in DAS28–ESR at week 24 was on average 0.35 units (95% CI 0.12 to 0.84; n=1394) greater than in seronegative patients; this effect was not seen in placebo patients.
• Heterogeneity indices indicated significant uncertainty in the overall–effect model (Q=8.8, I=0.77; p=0.03 (χ² test)).
• Baseline Health Assessment Questionnaire score, pain visual analogue scale, swollen joint counts of 28 joints and race were significant contributors to this heterogeneity, with additional analysis indicating that these effects may predominate in early RA (methotrexate–naïve) populations.
• A dominant effect was seen in patients for whom one or more tumour necrosis factor inhibitors had failed.